Lumakras plus Vectibix improved overall survival and response rates in KRAS G12C-mutated metastatic colorectal cancer, despite not achieving statistical significance. The combination showed a 30% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback